Updates are available Erratum dated 2016-07-07
Click to view Erratum: https://doi.org/10.1038/gt.2016.44
-
Authors
Cao, H
Yu, W
Li, X
Wang, J
Gao, S
Holton, N E
Eliason, S
Sharp, T
Amendt, B A
- License Information
-
More Information
Article History
Received: 30 December 2015
Revised: 19 February 2016
Accepted: 25 February 2016
First Online: 2 March 2016
Competing interests
: Dr Amendt’s work has been funded by the NIH and Iowa BioVentures Center. He is the CSO of NaturemiRI and owns stock in the company, and the new miR inhibitor has been issued a patent. Dr Cao is listed on the patent. All the other authors declare no conflict of interest.
